D-Matrix says its chips can run inference workloads 10 times faster and using five times less energy than a standalone graphics processing unit from Nvidia. Like Cerebras, D-Matrix is trying to prove ...

It’s been three-and-a-half years since generative AI exploded onto the scene. In this past year, progress has continued its relentless pace: Vibe coding took off, companies embraced agentic workflows, ...

The looks are softer and more varied. The looks are softer and more varied. is the Verge’s weekend editor. He’s covered the tech industry for over 18 years and knows a thing or two about synths. In ...

So far, five Google icons have undergone gradient updates. 9to5Google can now report on a complete gradient redesign for Gmail and other Google Workspace apps. Google is addressing a major criticism ...

What really happens after you hit enter on that AI prompt? WSJ’s Joanna Stern heads inside a data center to trace the journey and then grills up some steaks to show just how much energy it takes to ...

The Assessor Matrix is a new crafting material that you can find in ARC Raiders as part of the Flashpoint update. This material can only be found during a specific map condition, and you’ll need it ...

Tim is a Contributor to MovieWeb, covering all things film and TV, and his talents have graced Game Rant and Screen Rant. He is an avid collector of physical media, with a movie collection in the ...

Data centers face a conundrum: how to power increasingly dense server racks using equipment that relies on century-old technology. Traditional transformers are bulky and hot, but a new generation of ...

Novavax secures a non-exclusive licensing deal with Pfizer, validating Matrix-M's platform value and shifting NVAX toward a technology provider model. NVAX receives $30M upfront, a potential $500M in ...

Per the terms of the agreement, Novavax will receive an upfront payment of $30 million from Pfizer and is eligible to earn up to $500 million in potential development and commercial milestone payments ...

Beyond a $30 million upfront payment, Novavax could be in line for up to $500 million in development and sales milestones as part of a new deal with Pfizer. (iStock/Getty Images Plus) Pfizer is paying ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments. The biotech company said ...